What is VXRT's current stock price?

VXRT (Vaxart, Inc.) is currently trading at $0.64 with a market cap of $154.9M.

What sector is Vaxart, Inc. in?

Vaxart, Inc. (VXRT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VXRT a good stock to buy?

Analysts have a Buy consensus on VXRT with a price target of $2.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VXRT Vaxart, Inc.

Healthcare

$0.64-5.88%ClosedMarket Cap: $154.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

9.17

PEG

0.07

P/B

1.64

P/S

0.61

EV/EBITDA

2.37

DCF Value

$-34.02

FCF Yield

9.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

14.9%

Net Margin

14.5%

ROE

61.4%

ROA

20.6%

ROIC

35.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$39.2M	$5.2M	$—
Q4 null	$104.2M	$55.0M	$—
FY null	$237.3M	$16.3M	$—
Q3 null	$72.4M	$-8.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.00

Target (Median)

$2.00

Target Range

$2.00 - $2.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Grasman Jeroen Nicolaasofficer: Chief Financial Officer

SellThu May 21

BREITMEYER JAMES Bdirector

SellFri May 01

BREITMEYER JAMES Bdirector

SellFri May 01

BREITMEYER JAMES Bdirector:

SellFri May 01

Tucker Seanofficer: SVP, Chief Scientific Officer

SellTue Mar 31

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.18

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Peers